Objective
The main goal of this project is to build a realistic, human-based 3D pancreas model that includes insulin-producing β-cells, neighboring exocrine cells, and a network of tiny blood vessels. This model will allow researchers to study, in real time, how different pancreatic cell types communicate, how inflammation spreads, and how β-cells become damaged during the early stages of T1D. By combining 3D bioprinting, microfluidics (which mimics blood flow), and AI-assisted analysis, the project aims to create a fully functional “mini-pancreas” that behaves much like human tissue. Scientists will use this model to explore how immune signals and local stress pathways trigger β-cell failure and to identify ways to stop or reverse this process. The ultimate objective is to provide a new, reliable, and ethical platform for testing potential treatments that protect β-cells or promote their regeneration, reducing the need for animal experiments and improving translation to human disease.
Background Rationale
T1D arises when the immune system attacks the body’s own β cells, which produce insulin to control blood sugar levels. Despite decades of research, we still do not fully understand why this happens or why some people develop the disease while others do not. The pancreas is a complex organ made up of many cell types that work together, including β-cells, other hormone-producing islet cells, exocrine cells that secrete digestive enzymes, and a dense network of blood vessels. Disturbances in this environment can make β-cells more sensitive to immune attack or stress. Traditional research models such as mouse models or isolated human islets cannot reproduce these intricate interactions. Animal models differ in key immune and metabolic pathways, while isolated cell cultures lack the structural and vascular context of a real human pancreas. Our approach uses recent breakthroughs in 3D bioprinting, microfluidic systems, and AI-based spatial biology to recreate this complexity. By integrating human cells into a living, vascularized tissue that mirrors the natural pancreas, we can directly study how immune and inflammatory cues drive β-cell damage, and how this might be prevented or reversed.
Description of Project
Type 1 diabetes (T1D) develops when the body’s immune system mistakenly destroys insulin-producing β-cells in the pancreas, leading to a lifelong dependence on insulin injections. Although immune attack is the key driver, the disease is far more complex than an immune disorder alone. Recent studies show that other pancreatic cells such as those in the exocrine tissue and surrounding blood vessels also show early signs of stress and inflammation, suggesting that the entire pancreatic environment may influence how T1D begins and progresses. However, understanding these early events has been difficult because current laboratory models are too simple and animal models do not fully mimic the human pancreas. To overcome these barriers, our project will develop the first vascularized 3D “mini-pancreas”, built from human pancreatic and blood vessel cells using advanced 3D bioprinting and microfluidic technology. This living tissue model will replicate how blood flow, nutrient exchange, and immune signals affect β-cell health. We will also use artificial intelligence (AI) to compare our printed tissues with real human pancreas samples and improve the model’s accuracy over time. Once established, this system will allow researchers to study how inflammation and immune cells damage human β-cells and to test protective drugs or regenerative strategies in a realistic, animal-free human model. Ultimately, this approach could accelerate the discovery of therapies that preserve β-cell function and prevent the onset of T1D
Anticipated Outcome
This project will develop the first fully vascularized, multicellular human “mini-pancreas” model that can survive and function in laboratory conditions. The model will reproduce key features of the real human pancreas, including blood flow, nutrient exchange, and interactions between β-cells, exocrine tissue, and immune signals. With this platform, researchers will be able to: (1) Observe how inflammatory molecules and immune-like signals harm β-cells in real time. (2) Identify biological pathways that make β-cells more resilient or susceptible to stress. (3) Test new compounds or interventions that could protect β-cells from immune attack. The technology will also significantly reduce reliance on animal models, offering a human-specific system for understanding disease mechanisms and preclinical testing. Over the long term, this work could accelerate the development of β-cell–preserving or regenerative therapies, bringing us closer to preventing T1D onset or achieving lasting remission without lifelong insulin treatment.
Relevance to T1D
This research directly targets one of the most urgent gaps in T1D research: the lack of realistic human models that reflect how pancreatic β-cells interact with their surrounding environment. While immune dysfunction remains central to T1D, it is now clear that the exocrine tissue, blood vessels, and local inflammatory environment all contribute to disease onset and progression. By integrating these components into a single 3D bioprinted, vascularized pancreas model, this project provides a new window into how β-cells fail in T1D and how they might be protected. The system will enable detailed study of both β-cell–intrinsic and microenvironmental factors that trigger cell death or dysfunction. In addition, the platform can be used to test novel therapeutic compounds, gene targets, or regenerative approaches before moving to clinical studies. Because it is entirely based on human cells and tissues, it offers a more ethical, accurate, and scalable alternative to animal testing. Ultimately, this project aims to transform how T1D is studied and treatedhelping researchers and clinicians move from reactive insulin replacement to proactive strategies that maintain or restore the body’s natural insulin-producing capacity.